JPWO2020089343A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020089343A5 JPWO2020089343A5 JP2021523658A JP2021523658A JPWO2020089343A5 JP WO2020089343 A5 JPWO2020089343 A5 JP WO2020089343A5 JP 2021523658 A JP2021523658 A JP 2021523658A JP 2021523658 A JP2021523658 A JP 2021523658A JP WO2020089343 A5 JPWO2020089343 A5 JP WO2020089343A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- stimulating
- stationary phase
- streptavidin
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 202
- 230000004936 stimulating Effects 0.000 claims description 153
- 230000005526 G1 to G0 transition Effects 0.000 claims description 100
- 239000003153 chemical reaction reagent Substances 0.000 claims description 86
- 108010090804 Streptavidin Proteins 0.000 claims description 76
- 230000027455 binding Effects 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 59
- 239000000126 substance Substances 0.000 claims description 54
- 239000003550 marker Substances 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 44
- 210000004027 cells Anatomy 0.000 claims description 39
- 239000002269 analeptic agent Substances 0.000 claims description 29
- 102000004965 antibodies Human genes 0.000 claims description 29
- 108090001123 antibodies Proteins 0.000 claims description 29
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 26
- 239000011230 binding agent Substances 0.000 claims description 21
- 230000000977 initiatory Effects 0.000 claims description 21
- 210000000662 T-Lymphocyte Subsets Anatomy 0.000 claims description 20
- 229960002685 biotin Drugs 0.000 claims description 20
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims description 20
- 150000001615 biotins Chemical class 0.000 claims description 18
- 230000035693 Fab Effects 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 230000005484 gravity Effects 0.000 claims description 14
- 238000003306 harvesting Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000000638 stimulation Effects 0.000 claims description 13
- 102100019461 CD28 Human genes 0.000 claims description 12
- 101700033362 CD28 Proteins 0.000 claims description 12
- 102000000584 Calmodulin Human genes 0.000 claims description 12
- 108010041952 Calmodulin Proteins 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 239000002609 media Substances 0.000 claims description 11
- 108090001008 Avidin Proteins 0.000 claims description 10
- 102100008151 CCR7 Human genes 0.000 claims description 10
- 108010020195 FLAG peptide Proteins 0.000 claims description 10
- 101700036258 MECOM Proteins 0.000 claims description 10
- XZWYTXMRWQJBGX-VXBMVYAYSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carbox Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 claims description 9
- 101700056583 CD27 Proteins 0.000 claims description 9
- 102100019459 CD27 Human genes 0.000 claims description 9
- 230000003612 virological Effects 0.000 claims description 9
- 102000007312 Recombinant Proteins Human genes 0.000 claims description 8
- 108010033725 Recombinant Proteins Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 235000000638 D-biotin Nutrition 0.000 claims description 6
- 239000011665 D-biotin Substances 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 238000002617 apheresis Methods 0.000 claims description 5
- 239000012504 chromatography matrix Substances 0.000 claims description 5
- 230000000875 corresponding Effects 0.000 claims description 5
- 230000002708 enhancing Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 229920002395 Aptamer Polymers 0.000 claims description 4
- 102100003729 CD40LG Human genes 0.000 claims description 4
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 101700079540 FAS Proteins 0.000 claims description 4
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 101700026084 THY1 Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000038129 antigens Human genes 0.000 claims description 4
- 108091007172 antigens Proteins 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 108091022076 maltose binding proteins Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 230000003100 immobilizing Effects 0.000 claims description 3
- 210000004369 Blood Anatomy 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 229940022766 EGTA Drugs 0.000 claims description 2
- 102100016439 FAS Human genes 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 101700026790 LAT Proteins 0.000 claims description 2
- 101700005306 LYC1 Proteins 0.000 claims description 2
- 210000000265 Leukocytes Anatomy 0.000 claims description 2
- 210000004698 Lymphocytes Anatomy 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102100004033 SPNS1 Human genes 0.000 claims description 2
- 101700027603 SPNS1 Proteins 0.000 claims description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100008333 THY1 Human genes 0.000 claims description 2
- 102100008790 TNFRSF14 Human genes 0.000 claims description 2
- 101710040448 TNFRSF4 Proteins 0.000 claims description 2
- 102100013135 TNFRSF4 Human genes 0.000 claims description 2
- 230000003213 activating Effects 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 238000005138 cryopreservation Methods 0.000 claims description 2
- 230000001082 cryoprotectant Effects 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 210000003071 memory T lymphocyte Anatomy 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 230000002062 proliferating Effects 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000001177 retroviral Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims 5
- 102000005720 Glutathione Transferase family Human genes 0.000 claims 1
- 108010070675 Glutathione Transferase family Proteins 0.000 claims 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 claims 1
- MYVYPSWUSKCCHG-JQWIXIFHSA-N Trp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 MYVYPSWUSKCCHG-JQWIXIFHSA-N 0.000 claims 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 description 5
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000002443 helper T lymphocyte Anatomy 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753911P | 2018-10-31 | 2018-10-31 | |
| US62/753,911 | 2018-10-31 | ||
| US201962842511P | 2019-05-02 | 2019-05-02 | |
| US62/842,511 | 2019-05-02 | ||
| US201962861314P | 2019-06-13 | 2019-06-13 | |
| US62/861,314 | 2019-06-13 | ||
| PCT/EP2019/079746 WO2020089343A1 (fr) | 2018-10-31 | 2019-10-30 | Procédés de sélection et de stimulation de cellules et appareil associé |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512872A JP2022512872A (ja) | 2022-02-07 |
| JPWO2020089343A5 true JPWO2020089343A5 (fr) | 2022-11-07 |
| JP7582940B2 JP7582940B2 (ja) | 2024-11-13 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240191188A1 (en) | Methods for culturing cells and kits and apparatus for same | |
| US20230295567A1 (en) | Methods for culturing cells and kits and apparatus for same | |
| US20240101613A1 (en) | Oligomeric particle reagents and methods of use thereof | |
| US20210115401A1 (en) | Methods and Materials for the Generation of Regulatory T Cells | |
| EP3877054B1 (fr) | Procédé de production de cellules t génétiquement modifiées | |
| KR20210057730A (ko) | 조작 세포 및 이의 조성물 생성 방법 | |
| CN108472346A (zh) | 含有traf诱导结构域的嵌合受体及相关组合物和方法 | |
| CA3117568A1 (fr) | Procedes de selection et de stimulation de cellules et appareil associe | |
| RU2016145424A (ru) | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии | |
| WO2016166568A1 (fr) | Procédés, kits et appareil permettant d'augmenter une population de cellules | |
| CA3159380A1 (fr) | Dispositifs de selection et/ou stimulation de cellules et procedes d'utilisation | |
| JP2024517863A (ja) | 細胞を刺激し、形質導入する方法 | |
| JPWO2020089343A5 (fr) | ||
| RU2777989C2 (ru) | Олигомерные реагенты в виде частиц и способы их применения | |
| RU2778411C2 (ru) | Способы культивирования клеток и наборы и устройство для них |